Orchestra BioMed Holdings, Inc.OBIONASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
1.26%
↓ 87% below average
Average (18q)
9.32%
Historical baseline
Range
High:44.76%
Low:-13.91%
Volatility
629.4%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 1.26% |
| Q2 2025 | 2.75% |
| Q1 2025 | 22.89% |
| Q4 2024 | -5.38% |
| Q3 2024 | 4.22% |
| Q2 2024 | 22.10% |
| Q1 2024 | 7.06% |
| Q4 2023 | -0.55% |
| Q3 2023 | 0.69% |
| Q2 2023 | 2.97% |
| Q1 2023 | 9.43% |
| Q4 2022 | 27.87% |
| Q3 2022 | 17.30% |
| Q2 2022 | 44.76% |
| Q1 2022 | -1.61% |
| Q4 2021 | -3.50% |
| Q3 2021 | 38.76% |
| Q2 2021 | -13.91% |
| Q1 2021 | 0.00% |